BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10979074)

  • 21. Antidepressant activity of hyperforin conjugates of the St. John's wort, Hypericum perforatum Linn.: an experimental study.
    Muruganandam AV; Bhattacharya SK; Ghosal S
    Indian J Exp Biol; 2001 Dec; 39(12):1302-4. PubMed ID: 12018529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of hyperforin content of Hypericum perforatum (St John's Wort) extracts with their effects on alcohol drinking in C57BL/6J mice: a preliminary study.
    Wright CW; Gott M; Grayson B; Hanna M; Smith AG; Sunter A; Neill JC
    J Psychopharmacol; 2003 Dec; 17(4):403-8. PubMed ID: 14870952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variability in St. John's wort formulations is an important consideration.
    Kroll DJ; Shaw HS; Wall ME; Oberlies NH
    Altern Ther Health Med; 2001; 7(6):21-2. PubMed ID: 11712467
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of German St. John's wort products according to hyperforin and total hypericin content.
    Wurglics M; Westerhoff K; Kaunzinger A; Wilke A; Baumeister A; Dressman J; Schubert-Zsilavecz M
    J Am Pharm Assoc (Wash); 2001; 41(4):560-6. PubMed ID: 11486982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug?
    Laggner H; Schreier S; Hermann M; Exner M; Mühl A; Gmeiner BM; Kapiotis S
    Free Radic Res; 2007 Feb; 41(2):234-41. PubMed ID: 17364950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort.
    Kumar V; Mdzinarishvili A; Kiewert C; Abbruscato T; Bickel U; van der Schyf CJ; Klein J
    J Pharmacol Sci; 2006 Sep; 102(1):47-54. PubMed ID: 16936454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperforin, the active component of St. John's wort, induces IL-8 expression in human intestinal epithelial cells via a MAPK-dependent, NF-kappaB-independent pathway.
    Zhou C; Tabb MM; Sadatrafiei A; Grün F; Sun A; Blumberg B
    J Clin Immunol; 2004 Nov; 24(6):623-36. PubMed ID: 15622447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?
    Kholghi G; Arjmandi-Rad S; Zarrindast MR; Vaseghi S
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Jun; 395(6):629-642. PubMed ID: 35294606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurement of hyperforin a constituent of St. John's wort in plasma by high-performance liquid chromatography.
    Chi JD; Franklin M
    J Chromatogr B Biomed Sci Appl; 1999 Dec; 735(2):285-8. PubMed ID: 10670742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of hyperforin in the pharmacological activities of St. John's Wort.
    Zanoli P
    CNS Drug Rev; 2004; 10(3):203-18. PubMed ID: 15492771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An in vitro and hydroponic growing system for hypericin, pseudohypericin, and hyperforin production of St. John's wort (Hypericum perforatum CV new stem).
    Murch SJ; Rupasinghe HP; Saxena PK
    Planta Med; 2002 Dec; 68(12):1108-12. PubMed ID: 12494339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of St. John's wort on free radical production.
    Hunt EJ; Lester CE; Lester EA; Tackett RL
    Life Sci; 2001 Jun; 69(2):181-90. PubMed ID: 11441908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of eluent pH on the HPLC-UV analysis of hyperforin from St. John's Wort (Hypericum perforatum L.).
    Fourneron JD; Naït-Si Y
    Phytochem Anal; 2006; 17(2):71-7. PubMed ID: 16634282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.
    Laakmann G; Schüle C; Baghai T; Kieser M
    Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():54-9. PubMed ID: 9684948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypericum perforatum, a source of neuroactive lead structures.
    Verotta L
    Curr Top Med Chem; 2003; 3(2):187-201. PubMed ID: 12570773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of St John's wort (Hypericum perforatum).
    Wheatley D
    Lancet; 2000 Feb; 355(9203):576. PubMed ID: 10683029
    [No Abstract]   [Full Text] [Related]  

  • 37. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.
    Wurglics M; Schubert-Zsilavecz M
    Clin Pharmacokinet; 2006; 45(5):449-68. PubMed ID: 16640452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of action of St John's wort in depression : what is known?
    Butterweck V
    CNS Drugs; 2003; 17(8):539-62. PubMed ID: 12775192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The administration of St. John's wort (Hypericum perforatum) in the treatment of depression].
    Koszewska I
    Psychiatr Pol; 2001; 35(2):199-210. PubMed ID: 11490885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. St John's wort interaction with digoxin.
    Cheng TO
    Arch Intern Med; 2000 Sep; 160(16):2548. PubMed ID: 10979073
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.